drugset / Trial / NCT01212913
Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM)
RandomizedParallel-groupOpen-labelTreatment
Summary
Primary Objective: To demonstrate the non-inferiority of hemoglobin A1c (HbA1c) control at six months between the basal plus one and the biphasic insulin regimen. Secondary Objective: To demonstrate favorable outcome for basal plus over biphasic insulin when it comes to comparing when both hemoglobin A1c (HbA1c) target goal achievement and non-hypoglycemic event is taken into account.
Timeline
- Start
- 2010-08
- Primary completion
- 2012-05
- Completion
- 2012-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Insulin glulisine | Protein / enzyme biologic | 4 iu | Subcutaneous |
| Comparator | insulin aspart | Protein / enzyme biologic | 6 iu | Subcutaneous |
| Subject | insulin glargine | Protein / enzyme biologic | — | Subcutaneous |